Table 2 Demographic data at first available serum sample.

From: Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies

 

Total IIM (n = 44)

Anti-Jo1+ (n = 19)

Anti-Jo1− (n = 25)

Age, mean years (SD)

58.6 (11.7)

54.5 (11.2)

61.8 (11.1)

Women, n (%)

24 of 44 (54.5)

9 of 19 (47.4)

15 of 25 (60.0)

PM/DM/IBM, %

65/30/5

79/21/0

56/36/8

Disease duration in months, median (25–75th percentiles)

24 (0–60)

36 (12–60)

12 (0–54)

Anti-synthetase syndrome, n (%)

28 (63.6)

19 of 19 (100)

9 of 25 (36.0)a

Extra-muscular manifestations, n (%)

Interstitial Lung Disease, n (%)

25 (58.1)

16 of 19 (84.2)

9 of 25 (36.0)b

Arthritis

18 of 44 (40.9)

11 of 19 (57.9)

7 of 25 (28.0)

Dysphagia

9 of 44 (20.5)

3 of 19 (15.8)

6 of 25 (24.0)

Skin rash

14 of 44 (31.8)

5 of 19 (26.3)

9 of 25 (36.0)

Smoking status, n ever (%)

24 of 44 (54.5)

10 of 19 (52.6)

14 of 25 (56.0)

Laboratory tests

CK, median µcat/L (25–75th percentiles)

3.4 (1.3–12.7)

1.3 (1–7.9)

4.4 (1.7–15.7)c

Antibodies

Positive anti-PL7, n (%)

2 (5.1)

0

2 (8.3)

Positive anti-PL12, n (%)

2 (5.1)

0

2 (8.3)

Positive anti-EJ, n (%)

1 (2.5)

0

1 (4.2)

Positive anti-OJ, n (%)

3 (7.7)

0

3 (12.5)

Positive anti-Mi-2, n (%)

3 (7.9)

1 (7.1)

2 (8.3)

Positive anti-SRP, n (%)

2 (5.1)

0

2 (8.3)

Positive anti-MDA5, n (%)

3 (7.9)

0

3 (12.5)

Positive anti-TIF1g, n (%)

3 (7.9)

0

3 (12.5)

Positive anti-SSA, n (%)

16 (36.4)

10 (52.6)

6 (24.0)

Positive anti-SSB, n (%)

0

0

0

Positive anti-U1 RNP, n (%)

5 (11.4)

2 (10.5)

3 (12.0)

Positive anti-Ku, n (%)

1 (2.5)

0

1 (4)

Positive anti-PmScl, n (%)

2 (4.9)

1 (6.3)

1 (4)

Physician VAS, median (25–75th percentiles)

37 (10–50)

37 (0–60)

35 (12–50)

Patient VAS, median (25–75th percentiles)

28 (8–52)

21 (6–47)

32 (8–55)

MDAAT, median (25–75th percentiles)

0.06 (0–0.15)

0.07 (0–0.16)

0.06 (0–0.15)

HAQ (1–3), median (25–75th percentiles)

0.75 (0–1.41)

0.63 (0.13–1.25)

1 (0–1.5)

MMT-8 (0–80), median (25–75th percentiles)

78 (68–80)

80 (77–80)

75 (64–80)d

Immunosuppressive (IS) treatment, n (%)*

No treatment

10 (23)

4 (21)

6 (24)

1 treatment

12 (27)

3 (16)

9 (36)

2 or 3 concomitant treatments

22 (50)

12 (63)

10 (40)

Healthy controls (n = 24)

Age, mean years (SD)

59.3 (13.0)

  

Women, n (%)

12 of 24 (50)

  
  1. IIM, idiopathic inflammatory myopathies; VAS physician, physician’s global disease activity assessment; VAS patient, patient’s global disease activity assessment; MDDAT, Myositis Disease Activity Assessment Tool for extramuscular global assessment; HAQ, Health Assessment Questionnaire; MMT-8, Manual Muscle Testing; *1 treatment designates one of the following treatments alone: methotrexate, glucocorticoids, intravenous Ig, abatacept or azathioprine (AZA); 2 or 3 concomitant treatments designate all the possible following combinations: glucocorticoids + AZA, glucocorticoids + cyclophosphamide, glucocorticoids + methotrexate, glucocorticoids + mycophenolate mofetil, glucocorticoids + rituximab, glucocorticoids + cyclophosphamide+ rituximab, glucocorticoids + methotrexate +rituximab, or glucocorticoids + mycophenolate mofetil+rituximab. Missing information on VAS physician: 5 anti-Jo1− and 4 anti-Jo1+ patients; Missing information on VAS patient: 6 anti-Jo1− and 4 anti-Jo1+; Missing information on MDAAT: 10 anti-Jo1− and 6 anti-Jo1+; Missing information on HAQ: 6 anti-Jo1− and 4 anti-Jo1+; Missing information on MMT-8: 4 anti-Jo1− and 3 anti-Jo1+. ap < 0.001; bp = 0.002 vs anti-Jo1+ (Fisher’s test); cp = 0.018 vs anti-Jo1+ and dp = 0.015 vs anti-Jo1+ (Mann-Whitney test).
Back to article page